Depomed (DEPO) Misses Q1 EPS by 7c; Guides Below
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
DepoMed Inc (DEPO) PT Lowered to $13 at RBC Capital; Magnitude of Reset was a Suprise
May 10, 2017 6:24 AM EDTRBC Capital lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $13.00 (from $19.00) while maintaining a Sector Perform rating following a sizable reset on outlook.
Analyst Randall Stanicky said the reset is not a surprise given new CEO but magnitude... More
Piper Jaffray Upgrades DepoMed Inc (DEPO) to Neutral
May 10, 2017 4:54 AM EDTPiper Jaffray upgraded DepoMed Inc (NASDAQ: DEPO) from Underweight to Neutral with a price target of $10.00 (from $11.00).
Analyst David Amsellem believes the company multiple is reflective of the company's "relatively murky prospects" when it comes to LT growth opportunities.
FY 2017 EPS estimate... More



